Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
33
EWTX Quote, Financials, Valuation and Earnings
Last price:
$28.83
Seasonality move
:
-23.32%
Day range:
$28.60 - $30.26
52-week range:
$10.60 - $31.82
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
6.02x
Volume:
687.7K
Avg. volume:
962.7K
1-year change:
13.49%
Market cap:
$3.1B
Revenue:
--
EPS (TTM):
-$1.63
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
EWTX
Edgewise Therapeutics, Inc.
|
-- | -$0.44 | -- | -14.83% | $40.17 |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$12.1M | -$1.95 | 59.92% | -15.51% | $38.88 |
|
GKOS
Glaukos Corp.
|
$137M | -$0.20 | 28.42% | -14.86% | $134.79 |
|
NBIX
Neurocrine Biosciences, Inc.
|
$789.3M | $2.30 | 34.66% | 2140.2% | $177.11 |
|
NUVL
Nuvalent, Inc.
|
-- | -$1.44 | -- | -12.74% | $143.53 |
|
OMER
Omeros Corp.
|
-- | $0.36 | -- | -2.38% | $38.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
EWTX
Edgewise Therapeutics, Inc.
|
$29.70 | $40.17 | $3.1B | -- | $0.00 | 0% | -- |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$29.20 | $38.88 | $1.7B | 3.91x | $0.00 | 0% | 31.33x |
|
GKOS
Glaukos Corp.
|
$121.12 | $134.79 | $7B | -- | $0.00 | 0% | 13.65x |
|
NBIX
Neurocrine Biosciences, Inc.
|
$132.38 | $177.11 | $13.3B | 28.36x | $0.00 | 0% | 4.74x |
|
NUVL
Nuvalent, Inc.
|
$101.29 | $143.53 | $7.4B | -- | $0.00 | 0% | -- |
|
OMER
Omeros Corp.
|
$11.98 | $38.00 | $849.4M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
EWTX
Edgewise Therapeutics, Inc.
|
0.76% | 0.586 | 0.15% | 19.37x |
|
AGIO
Agios Pharmaceuticals, Inc.
|
3.26% | 2.174 | 2.53% | 10.52x |
|
GKOS
Glaukos Corp.
|
13.97% | 0.983 | 1.64% | 3.91x |
|
NBIX
Neurocrine Biosciences, Inc.
|
12.65% | 1.412 | 3.32% | 2.92x |
|
NUVL
Nuvalent, Inc.
|
-- | 0.585 | -- | 15.05x |
|
OMER
Omeros Corp.
|
254.22% | -2.830 | 126.5% | 0.76x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
EWTX
Edgewise Therapeutics, Inc.
|
-$575K | -$56M | -32.51% | -32.79% | -- | -$38.7M |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$16.8M | -$121.6M | -29.08% | -30.11% | -608.9% | -$97.3M |
|
GKOS
Glaukos Corp.
|
$111.4M | -$27M | -22.09% | -25.22% | -18.87% | -$12.7M |
|
NBIX
Neurocrine Biosciences, Inc.
|
$787.9M | $227.9M | 14.5% | 17% | 28.29% | $390.8M |
|
NUVL
Nuvalent, Inc.
|
-- | -$102.2M | -41.59% | -41.59% | -- | -$73.3M |
|
OMER
Omeros Corp.
|
-$240K | -$26.4M | -59.56% | -- | -- | -$18.5M |
Edgewise Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns EWTX or AGIO?
Agios Pharmaceuticals, Inc. has a net margin of -- compared to Edgewise Therapeutics, Inc.'s net margin of -541.09%. Edgewise Therapeutics, Inc.'s return on equity of -32.79% beat Agios Pharmaceuticals, Inc.'s return on equity of -30.11%.
Company Gross Margin Earnings Per Share Invested Capital EWTXEdgewise Therapeutics, Inc.-- -$0.47 $526.2M AGIOAgios Pharmaceuticals, Inc.84.25% -$1.85 $1.2B -
What do Analysts Say About EWTX or AGIO?
Edgewise Therapeutics, Inc. has a consensus price target of $40.17, signalling upside risk potential of 35.24%. On the other hand Agios Pharmaceuticals, Inc. has an analysts' consensus of $38.88 which suggests that it could grow by 33.13%. Given that Edgewise Therapeutics, Inc. has higher upside potential than Agios Pharmaceuticals, Inc., analysts believe Edgewise Therapeutics, Inc. is more attractive than Agios Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EWTXEdgewise Therapeutics, Inc.7 2 0 AGIOAgios Pharmaceuticals, Inc.7 3 0 -
Is EWTX or AGIO More Risky?
Edgewise Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Agios Pharmaceuticals, Inc. has a beta of 0.895, suggesting its less volatile than the S&P 500 by 10.538%.
-
Which is a Better Dividend Stock EWTX or AGIO?
Edgewise Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agios Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edgewise Therapeutics, Inc. pays -- of its earnings as a dividend. Agios Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EWTX or AGIO?
Edgewise Therapeutics, Inc. quarterly revenues are --, which are smaller than Agios Pharmaceuticals, Inc. quarterly revenues of $20M. Edgewise Therapeutics, Inc.'s net income of -$50.2M is higher than Agios Pharmaceuticals, Inc.'s net income of -$108M. Notably, Edgewise Therapeutics, Inc.'s price-to-earnings ratio is -- while Agios Pharmaceuticals, Inc.'s PE ratio is 3.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edgewise Therapeutics, Inc. is -- versus 31.33x for Agios Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EWTXEdgewise Therapeutics, Inc.-- -- -- -$50.2M AGIOAgios Pharmaceuticals, Inc.31.33x 3.91x $20M -$108M
-
Which has Higher Returns EWTX or GKOS?
Glaukos Corp. has a net margin of -- compared to Edgewise Therapeutics, Inc.'s net margin of -93.39%. Edgewise Therapeutics, Inc.'s return on equity of -32.79% beat Glaukos Corp.'s return on equity of -25.22%.
Company Gross Margin Earnings Per Share Invested Capital EWTXEdgewise Therapeutics, Inc.-- -$0.47 $526.2M GKOSGlaukos Corp.77.8% -$2.32 $762.7M -
What do Analysts Say About EWTX or GKOS?
Edgewise Therapeutics, Inc. has a consensus price target of $40.17, signalling upside risk potential of 35.24%. On the other hand Glaukos Corp. has an analysts' consensus of $134.79 which suggests that it could grow by 11.28%. Given that Edgewise Therapeutics, Inc. has higher upside potential than Glaukos Corp., analysts believe Edgewise Therapeutics, Inc. is more attractive than Glaukos Corp..
Company Buy Ratings Hold Ratings Sell Ratings EWTXEdgewise Therapeutics, Inc.7 2 0 GKOSGlaukos Corp.10 0 1 -
Is EWTX or GKOS More Risky?
Edgewise Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Glaukos Corp. has a beta of 0.697, suggesting its less volatile than the S&P 500 by 30.259%.
-
Which is a Better Dividend Stock EWTX or GKOS?
Edgewise Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Glaukos Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edgewise Therapeutics, Inc. pays -- of its earnings as a dividend. Glaukos Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EWTX or GKOS?
Edgewise Therapeutics, Inc. quarterly revenues are --, which are smaller than Glaukos Corp. quarterly revenues of $143.1M. Edgewise Therapeutics, Inc.'s net income of -$50.2M is higher than Glaukos Corp.'s net income of -$133.7M. Notably, Edgewise Therapeutics, Inc.'s price-to-earnings ratio is -- while Glaukos Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edgewise Therapeutics, Inc. is -- versus 13.65x for Glaukos Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EWTXEdgewise Therapeutics, Inc.-- -- -- -$50.2M GKOSGlaukos Corp.13.65x -- $143.1M -$133.7M
-
Which has Higher Returns EWTX or NBIX?
Neurocrine Biosciences, Inc. has a net margin of -- compared to Edgewise Therapeutics, Inc.'s net margin of 19.08%. Edgewise Therapeutics, Inc.'s return on equity of -32.79% beat Neurocrine Biosciences, Inc.'s return on equity of 17%.
Company Gross Margin Earnings Per Share Invested Capital EWTXEdgewise Therapeutics, Inc.-- -$0.47 $526.2M NBIXNeurocrine Biosciences, Inc.97.82% $1.48 $3.7B -
What do Analysts Say About EWTX or NBIX?
Edgewise Therapeutics, Inc. has a consensus price target of $40.17, signalling upside risk potential of 35.24%. On the other hand Neurocrine Biosciences, Inc. has an analysts' consensus of $177.11 which suggests that it could grow by 33.79%. Given that Edgewise Therapeutics, Inc. has higher upside potential than Neurocrine Biosciences, Inc., analysts believe Edgewise Therapeutics, Inc. is more attractive than Neurocrine Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EWTXEdgewise Therapeutics, Inc.7 2 0 NBIXNeurocrine Biosciences, Inc.19 4 0 -
Is EWTX or NBIX More Risky?
Edgewise Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Neurocrine Biosciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.196%.
-
Which is a Better Dividend Stock EWTX or NBIX?
Edgewise Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Neurocrine Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edgewise Therapeutics, Inc. pays -- of its earnings as a dividend. Neurocrine Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EWTX or NBIX?
Edgewise Therapeutics, Inc. quarterly revenues are --, which are smaller than Neurocrine Biosciences, Inc. quarterly revenues of $805.5M. Edgewise Therapeutics, Inc.'s net income of -$50.2M is lower than Neurocrine Biosciences, Inc.'s net income of $153.7M. Notably, Edgewise Therapeutics, Inc.'s price-to-earnings ratio is -- while Neurocrine Biosciences, Inc.'s PE ratio is 28.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edgewise Therapeutics, Inc. is -- versus 4.74x for Neurocrine Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EWTXEdgewise Therapeutics, Inc.-- -- -- -$50.2M NBIXNeurocrine Biosciences, Inc.4.74x 28.36x $805.5M $153.7M
-
Which has Higher Returns EWTX or NUVL?
Nuvalent, Inc. has a net margin of -- compared to Edgewise Therapeutics, Inc.'s net margin of --. Edgewise Therapeutics, Inc.'s return on equity of -32.79% beat Nuvalent, Inc.'s return on equity of -41.59%.
Company Gross Margin Earnings Per Share Invested Capital EWTXEdgewise Therapeutics, Inc.-- -$0.47 $526.2M NUVLNuvalent, Inc.-- -$1.59 $1.2B -
What do Analysts Say About EWTX or NUVL?
Edgewise Therapeutics, Inc. has a consensus price target of $40.17, signalling upside risk potential of 35.24%. On the other hand Nuvalent, Inc. has an analysts' consensus of $143.53 which suggests that it could grow by 41.7%. Given that Nuvalent, Inc. has higher upside potential than Edgewise Therapeutics, Inc., analysts believe Nuvalent, Inc. is more attractive than Edgewise Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EWTXEdgewise Therapeutics, Inc.7 2 0 NUVLNuvalent, Inc.14 0 0 -
Is EWTX or NUVL More Risky?
Edgewise Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nuvalent, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock EWTX or NUVL?
Edgewise Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuvalent, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edgewise Therapeutics, Inc. pays -- of its earnings as a dividend. Nuvalent, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EWTX or NUVL?
Edgewise Therapeutics, Inc. quarterly revenues are --, which are smaller than Nuvalent, Inc. quarterly revenues of --. Edgewise Therapeutics, Inc.'s net income of -$50.2M is higher than Nuvalent, Inc.'s net income of -$118.7M. Notably, Edgewise Therapeutics, Inc.'s price-to-earnings ratio is -- while Nuvalent, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edgewise Therapeutics, Inc. is -- versus -- for Nuvalent, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EWTXEdgewise Therapeutics, Inc.-- -- -- -$50.2M NUVLNuvalent, Inc.-- -- -- -$118.7M
-
Which has Higher Returns EWTX or OMER?
Omeros Corp. has a net margin of -- compared to Edgewise Therapeutics, Inc.'s net margin of --. Edgewise Therapeutics, Inc.'s return on equity of -32.79% beat Omeros Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital EWTXEdgewise Therapeutics, Inc.-- -$0.47 $526.2M OMEROmeros Corp.-- -$0.47 $143M -
What do Analysts Say About EWTX or OMER?
Edgewise Therapeutics, Inc. has a consensus price target of $40.17, signalling upside risk potential of 35.24%. On the other hand Omeros Corp. has an analysts' consensus of $38.00 which suggests that it could grow by 217.2%. Given that Omeros Corp. has higher upside potential than Edgewise Therapeutics, Inc., analysts believe Omeros Corp. is more attractive than Edgewise Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EWTXEdgewise Therapeutics, Inc.7 2 0 OMEROmeros Corp.2 2 0 -
Is EWTX or OMER More Risky?
Edgewise Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Omeros Corp. has a beta of 2.449, suggesting its more volatile than the S&P 500 by 144.921%.
-
Which is a Better Dividend Stock EWTX or OMER?
Edgewise Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omeros Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edgewise Therapeutics, Inc. pays -- of its earnings as a dividend. Omeros Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EWTX or OMER?
Edgewise Therapeutics, Inc. quarterly revenues are --, which are smaller than Omeros Corp. quarterly revenues of --. Edgewise Therapeutics, Inc.'s net income of -$50.2M is lower than Omeros Corp.'s net income of -$21.2M. Notably, Edgewise Therapeutics, Inc.'s price-to-earnings ratio is -- while Omeros Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edgewise Therapeutics, Inc. is -- versus -- for Omeros Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EWTXEdgewise Therapeutics, Inc.-- -- -- -$50.2M OMEROmeros Corp.-- -- -- -$21.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
50
AXTI alert for Mar 3
AXT, Inc. [AXTI] is down 9.65% over the past day.
Buy
53
AAOI alert for Mar 3
Applied Optoelectronics, Inc. [AAOI] is down 6.93% over the past day.
Sell
32
TPB alert for Mar 3
Turning Point Brands, Inc. [TPB] is down 0.87% over the past day.
